Complement Deficiencies

First-In-Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Escalating Single And Multiple Doses Of CSL040 In Healthy Subjects

NCT05937581 | Phase 1 | Interventional

First-In-Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Escalating Single And Multiple Doses Of CSL040 In Healthy Subjects

1 Sites

60 Participants

Recruiting

18 Years to 64 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Find closest sites:

SUBMIT

Nucleus Network Pty Ltd

Herston,Australia,4006

Study Eligibility Criteria

Inclusion Criteria

Male or female 18 to 64 years of age, inclusive, at Screening
Body weight in the range of ≥ 50 kg and ≤ 100 kg, with a body mass index of ≥ 18 kg/m2 and ≤ 30 kg/m2, at Screening
Judged as healthy by an Investigator after completion of a comprehensive clinical assessment
Capable of providing written informed consent and willing and able to adhere to all protocol requirements
Can understand the nature, scope, and possible consequences of the study and able to comply with study procedures, restrictions, and requirements
Able to provide proof of vaccination against meningococcal disease according to local requirements or willing to receive meningococcal vaccination aligned with local guidelines (vaccination with recombinant meningococcal B vaccine against B serogroup [Men B] and quadrivalent meningococcal conjugate vaccine against A, C, W, and Y serogroups [Men ACWY]), at least 21 days before the first dose of CSL040
Continuous nonsmoker who has not used nicotine- and tobacco-containing products for at least 30 days prior to the first dosing based on urine cotinine testing at Screening and Day-1

Exclusion Criteria

Any individual at high risk of exposure to Neisseria meningitidis, including, but not limited to, health care workers, doctors, nurses, students working in a clinical setting, laboratory workers with exposure to N. meningitidis, individuals residing in a dormitory setting (eg, military workers), and childcare workers
Other than the required meningococcal vaccines, any live vaccinations within the last 90 days before and during the study and / or up to 90 days after the last administration of the investigational product
A positive test result for hepatitis B surface antigen (HBsAg), hepatitis B core antigen, hepatitis B surface antibody, hepatitis C virus antibody, or human immunodeficiency virus-1/2 antibody.
History concerning for a N. meningitidis infection
History of allergy or intolerance to Penicillin V
History of unexplained, recurrent infection, life-threatening infection, or history that suggests any immunodeficiency (functional immunodeficiency), including asplenia / functional asplenia
Infection requiring treatment with systemic antibiotics (IV and / or oral administration for more than 3 days) within the last 90 days prior to dosing
Clinical evidence of current active serious infection, including any localized infections, or any infection which makes the participation in this study of healthy subjects unacceptably high risk
Blood pressure or pulse rate measurements outside the normal range for the subject's age and assessed as clinically significant
Known history of severe hypersensitivity reactions or suspected hypersensitivity to the CSL040 or any of the excipients or other monoclonal antibodies
Subject has any condition that may compromise their safety or compliance, impede successful conduct of the study, interfere with interpretation of the results or would otherwise render the subject unsuitable for participation in the study
A positive test result for drugs of abuse (including alcohol) at Screening and / or Day -1.
Weekly alcohol intake of > 10 units for females and > 14 units for males during the 3 months before Day -1.
Any values above the upper limit of normal (ULN) for alanine aminotransaminase (ALT) or aspartate aminotransaminase (AST), or bilirubin test result
Use of prescription or over-the-counter medication, herbal and dietary supplements, and vitamins and minerals (except the vaccination as required per protocol) within the 21 days before administration of investigational product
Female subject of childbearing potential or fertile male subject who are neither using nor willing to use a highly effective method of contraception
Pregnant, lactating, or breastfeeding
Donation or loss of more than 500 mL of blood within 3 months, or donated plasma within 7 days, before admission to the unit and for 5 half-lives or until the end of the study, whichever is longer
Any planned s

Additional Studies

Additional studies can be found at ClinicalTrials.gov